Persistent transgene expression following intravenous administration of a liposomal complex: Role of interleukin-10-mediated immune suppression

Molecular Therapy

Volumn 9, Issue 3, 2004, Pages 318-327

  Ito, Isao ^a,b   Saeki, Tomoyuki ^a,c   Mohuiddin, Imran ^a   Saito, Yuji ^a,c   Branch, Cynthia D ^a   Vaporciyan, Ara ^a   Roth, Jack A ^a   Ramesh, Rajagopal ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer; Cytokines; Gene expression; Gene therapy; IL 10; Inflammation; Liposome; Lung

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CHOLESTEROL; CYTOKINE; DNA; INTERLEUKIN 10; LIPOSOME; LUCIFERASE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; INFLAMMATION; LUNG CANCER; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUDE MOUSE; PROTEIN EXPRESSION; TRANSGENE;

MUS MUSCULUS; TRIXIS;

EID: 1642525197     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.01.007     Document Type: Article

References (54)

1. Whitmore, M., et al. (1999). LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 6: 1867-1875.
2. Huang, L., and Li, S. (1997). Liposomal gene delivery - a complex package. Nat. Biotechnol. 15: 620-621.
3. Li, S., et al. (1999). Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am. J. Physiol. 276: L796-L804.
4. Freimark, B. D., et al. (1998). Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid-cationic lipid complexes. J. Immunol. 160: 4580-4586.
5. Whitmore, M., et al. (1999). LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 6: 1867-1875.
6. Dow, S. W., et al. (1999). Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J. Immunol. 163: 1552-1561.
7. Scheule, R. K. J., et al. (1997). Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum. Gene Ther. 8: 689-707.
8. Tousignant, J. D., et al. (2003). DNA sequences in cationic lipid:pDNA-mediated systemic toxicities. Hum. Gene Ther. 14: 203-214.
9. Tan, Y., et al. (1999). The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector mediated transgene expression in vivo.Hum. Gene Ther. 10: 2153-2161.
10. Yew, N. S., et al. (2000). Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. Mol. Ther. 1: 255-262.
11. Schwartz, D. A., et al. (1997). Cpg motifs in bacterial DNA cause inflammation in the lower respiratory tract. J. Clin. Invest. 100: 68-73.
12. McLachlan, G., et al. (2000). Bacterial DNA is implicated in the inflammatory response to delivery of DNA/DOTAP to mouse lungs. Gene Ther. 7: 384-392.
13. Qin, L., et al. (1997). Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor alpha inhibit transgene expression. Hum. Gene Ther. 8: 2019-2029.
14. Li, S., et al. (1998). Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther. 5: 930-997.
15. Yew, N. S., et al. (2002). Cpg-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol. Ther. 5: 731-738.
16. Ramesh, R., et al. (2001). Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol. Ther. 3: 337-350.
17. Kuda, T., Yasumoto, K., Yano, T., Nakahashi, H., Sugimachi, K., and Nomoto, K. (1987). Role of antitumor activity of alveolar macrophages in lung cancer patients. Cancer Res. 47: 2199-2202.
18. Sotomayor, E. M., et al. (1993). Impaired activation of tumoricidal function in macrophages from mammary tumor bearers: The role of IFN-γ. Int. J. Oncol. 3: 719-727.
19. Sotomayor, E. M., et al. (1995). Decreased macrophage mediated cytotoxicity in mammary tumor bearing mice is related to alterations in nitric oxide production and/or release. Int. J. Cancer 60: 660-667.
20. Mazzoccoli, G., et al. (1999). Lymphocyte subpopulations anomalies in lung cancer patients and relationship to the stage of disease. In Vivo 13: 205-209.
21. Koutsami, M. K., Gorgoulis, V. G., Kastrinakis, N. G., Asimacopoulos, P. J., and Kittas, C. (2002). Prognostic factors in non-small cell lung carcinoma. Anticancer Res. 22: 347-374.
22. Sotomayor, E. M., et al. (1991). Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. J. Immunol. 147: 2816-2823.
23. Lopez, D. M., et al. (1996). Cytokine production by lymphoreticular cells from mammary tumor bearing mice: The role of tumor-derived factors. Anticancer Res. 16: 3923-3930.
24. Lopez, D. M., et al. (1991). Modulation of the immune system by mammary tumor derived factors. Cancer Invest. 9: 643-653.
25. Ghosh, P., et al. (1995). Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J. Natl. Cancer Inst. 87: 1478-1483.
26. Beutler, B., and Cerami, A. (1989). The biology of cachectin/TNF-α as primary mediator of host response. Annu. Rev. Immunol. 7: 625.
27. Ito, I., et al. (2003). Increased uptake of liposomal-DNA complexes by lung metastases following intravenous administration. Mol. Ther. 7: 409-418.
28. Vassali, P. (1992). The pathophysiology of tumor necrosis factor. Annu. Rev. Immunol. 10: 411.
29. Fiorentino, D. F., Zlotnik, A., Mossman, T., Howard, M., and O'Garra, A. (1991). IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147: 3815.
30. 2. J. Immunol. 153: 1674.
31. Kambayashi, T., Alexander, H. R., Fong, M., and Strassman, G. (1995). Potential involvement of IL-10 in suppressing tumor-associated macrophages. J. Immunol 154: 3383-3390.
32. Bogdan, C. Y., Vodovotz, Y., and Nathan, C. (1991). Macrophage deactivation by interleukin-10. J. Exp. Med. 174: 1549.
33. de Waal Malefyt, R., Abrams, J., Bennet, B., Figdor, C., and deVries, J. E. (1991). Interleukin-10 inhibits cytokine synthesis by human monocytes: An autoregulatory role for IL-10 production by monocytes. J. Exp. Med. 174: 1209.
34. Strassman, C., Koota, V., Finkelman, F., Fong, M., and Kambayashi, T. (1994). Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J. Exp. Med. 180: 2365.
35. Gastl, G. A., et al. (1993). Interleukin 10 production by human carcinoma cell lines and its relation to interleukin 6 expression. Int. J. Cancer. 55: 96.
36. Howard, M., and O'Garra, A. (1992). Biological properties of interleukin 10. Immunol. Today 13: 198.
37. Moore, K. W., et al. (1993). Interleukin-10. Annu. Rev. Immunol 11: 165-190.
38. Loercher, A. E., et al. (1999). Identification of an IL-10 producing HLA DR negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J. Immunol. 163: 6251-6260.
39. Gotlieb, W. H., et al. (1992). Presence of interleukin-10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 4: 385-390.
40. de Waal Malefyt, R., et al. (1991). IL-10 and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II MHC expression. J. Exp. Med. 174: 915-924.
41. Fiorentino, D. F., et al. (1991). L-10 acts on the antigen-presenting cells to inhibit cytokine production by Th1 cells. J. Immunol. 146: 3444-3451.
42. Ding, L., and Shevach, E. M. (1992). IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J. Immunol. 148: 3133-3139.
43. Bogdan, C., Vodovotz, Y., and Nathan, C. (1991). Macrophage deactivation by interleukin-10. J. Exp. Med. 174: 1549-1555.
44. Armstrong, L., Jordan, N., and Miller, A. (1996). Interleukin-10 (IL-10) regulation of tumor necrosis factor alpha (TNF-alpha) from human alveolar macrophages and peripheral blood monocytes. Thorax 51: 143-149.
45. Ralph, P., et al. (1992). IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J. Immunol. 148: 808-814.
46. + T cell clones and resting T cells. J. Immunol. 150: 4754-4765.
47. Yue, F. Y., et al. (1997). Interleukin-10 is a growth factor for human melanoma cells and downregulates HLA class-I, HLA class-II and ICAM-1 molecules. Int. J. Cancer 71: 630-637.
48. Lu, Z. Y., et al. (1995). Interleukin-10 is a proliferation factor but not differentiation factor for human myeloma cells. Blood 85: 2521-2527.
49. Masood, R., et al. (1995). Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 85: 3423-3430.
50. Templeton, N. S., et al. (1997). Improved DNA:lIposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol. 15: 647-652.
51. Moxley, M. A., Baird, T. L., and Corbett, J. A. (2000). Adoptive transfer of acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 279: 985-993.
52. Wan, X. S., Zhou, Z., and Kennedy, A. R. (2003). Adaptation of the dichlorofluorescein assay for detection of radiation-induced oxidative stress in cultured cells. Radiat. Res. 160: 622-630.
53. Goldsmith, C. A., Imrich, A., Danaee, H., Ning, Y. Y., and Kobzik, L. (1998). Analysis of air pollution particulate-mediated oxidant stress in alveolar macrophages. J. Toxicol. Environ. Health A 54: 529-545.
54. Tsai, J. J., Kao, M. H., and Han, S. H. (1999). The respiratory burst activity of activated eosinophils in atopic asthmatics. Int. Arch. Allergy Immunol. 119: 38-44.